Probiotics and prebiotics: Present status and future perspectives on metabolic disorders

Nutrients

Volumn 8, Issue 3, 2016, Pages

  Yoo, Ji Youn ^a   Kim, Sung Soo ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Cardiovascular diseases (CVD); Gut microbiota; Metabolic disorders; Prebiotics; Probiotics; Type 2 diabetes (T2DM)

Indexed keywords

CD36 ANTIGEN; CHOLESTEROL; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREBIOTIC AGENT; PROBIOTIC AGENT; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TRIMETHYLAMINE OXIDE; YOGHURT;

BIFIDOBACTERIUM LONGUM; CARDIOVASCULAR DISEASE; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; HUMAN; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; MESENTERIC FAT; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; MICROBIOLOGY; PROTECTION; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; PREBIOTICS; PROBIOTICS; PROTECTIVE FACTORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84962558135     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8030173     Document Type: Review

References (131)

1. Kasubuchi, M.; Hasegawa, S.; Hiramatsu, T.; Ichimura, A.; Kimura, I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients 2015, 7, 2839-2849. [CrossRef] [PubMed]
2. Nagatomo, Y.; Tang, W.H. Intersections between microbiome and heart failure: Revisiting the gut hypothesis. J. Card. Fail. 2015, 21, 973-980. [CrossRef] [PubMed]
3. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with obesity. Nature 2006, 444, 1022-1023. [CrossRef] [PubMed]
4. Hooper, L.V.; Wong, M.H.; Thelin, A.; Hansson, L.; Falk, P.G.; Gordon, J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001, 291, 881-884. [CrossRef] [PubMed]
5. DiBaise, J.K.; Zhang, H.; Crowell, M.D.; Krajmalnik-Brown, R.; Decker, G.A.; Rittmann, B.E. Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc. 2008, 83, 460-469. [CrossRef] [PubMed]
6. Brugman, S.; Klatter, F.A.; Visser, J.T.; Wildeboer-Veloo, A.C.; Harmsen, H.J.; Rozing, J.; Bos, N.A. Antibiotic treatment partially protects against type 1 diabetes in the bio-breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 2006, 49, 2105-2108. [CrossRef] [PubMed]
7. De la Serre, C.B.; Ellis, C.L.; Lee, J.; Hartman, A.L.; Rutledge, J.C.; Raybould, H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G440-G448. [CrossRef] [PubMed]
8. Fuller, R. Probiotics in man and animals. J. Appl. Bacteriol. 1989, 66, 365-378. [PubMed]
9. Gibson, G.R.; Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J. Nutr. 1995, 125, 1401-1412. [PubMed]
10. Cruchet, S.; Furnes, R.; Maruy, A.; Hebel, E.; Palacios, J.; Medina, F.; Ramirez, N.; Orsi, M.; Rondon, L.; Sdepanian, V.; et al. The use of probiotics in pediatric gastroenterology: A review of the literature and recommendations by latin-american experts. Paediatr. Drugs 2015, 17, 199-216. [CrossRef] [PubMed]
11. Verna, E.C.; Lucak, S. Use of probiotics in gastrointestinal disorders: What to recommend? Ther. Adv. Gastroenterol. 2010, 3, 307-319. [CrossRef] [PubMed]
12. Tan, S.Y.; Dee, M.K. Elie metchnikoff (1845-1916): Discoverer of phagocytosis. Singap. Med. J. 2009, 50, 456-457.
13. Lee, J.H.; O’Sullivan, D.J. Genomic insights into bifidobacteria. Microbiol. Mol. Biol. Rev. MMBR 2010, 74, 378-416. [CrossRef] [PubMed]
14. Tissier, H. Le bacterium coli et la reaction chromophile d’escherich. Crit. Rev. Soc. Biol. 1899, 51, 943-945.
15. Patterson, J.A.; Burkholder, K.M. Application of prebiotics and probiotics in poultry production. Poult. Sci. 2003, 82, 627-631. [CrossRef] [PubMed]
16. Ritzi, M.M.; Abdelrahman, W.; Mohnl, M.; Dalloul, R.A. Effects of probiotics and application methods on performance and response of broiler chickens to an eimeria challenge. Poult. Sci. 2014, 93, 2772-2778. [CrossRef] [PubMed]
17. Tuohy, K.M.; Probert, H.M.; Smejkal, C.W.; Gibson, G.R. Using probiotics and prebiotics to improve gut health. Drug Discov. Today 2003, 8, 692-700. [CrossRef]
18. Wong, J.M.; de Souza, R.; Kendall, C.W.; Emam, A.; Jenkins, D.J. Colonic health: Fermentation and short chain fatty acids. J. Clin. Gastroenterol. 2006, 40, 235-243. [CrossRef] [PubMed]
19. Calcinaro, F.; Dionisi, S.; Marinaro, M.; Candeloro, P.; Bonato, V.; Marzotti, S.; Corneli, R.B.; Ferretti, E.; Gulino, A.; Grasso, F.; et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005, 48, 1565-1575. [CrossRef] [PubMed]
20. Sun, J.; Buys, N. Effects of probiotics consumption on lowering lipids and CVD risk factors: A systematic review and meta-analysis of randomized controlled trials. Ann. Med. 2015, 47, 430-440. [CrossRef] [PubMed]
21. Matis, G.; Kulcsar, A.; Turowski, V.; Febel, H.; Neogrady, Z.; Huber, K. Effects of oral butyrate application on insulin signaling in various tissues of chickens. Domest. Anim. Endocrinol. 2015, 50, 26-31. [CrossRef] [PubMed]
22. Ejtahed, H.S.; Mohtadi-Nia, J.; Homayouni-Rad, A.; Niafar, M.; Asghari-Jafarabadi, M.; Mofid, V.; Akbarian-Moghari, A. Effect of probiotic yogurt containing lactobacillus acidophilus and bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J. Dairy Sci. 2011, 94, 3288-3294. [CrossRef] [PubMed]
23. Naito, E.; Yoshida, Y.; Makino, K.; Kounoshi, Y.; Kunihiro, S.; Takahashi, R.; Matsuzaki, T.; Miyazaki, K.; Ishikawa, F. Beneficial effect of oral administration of lactobacillus casei strain shirota on insulin resistance in diet-induced obesity mice. J. Appl. Microbiol. 2011, 110, 650-657. [CrossRef] [PubMed]
24. Roller, M.; Rechkemmer, G.; Watzl, B. Prebiotic inulin enriched with oligofructose in combination with the probiotics lactobacillus rhamnosus and bifidobacterium lactis modulates intestinal immune functions in rats. J. Nutr. 2004, 134, 153-156. [PubMed]
25. Wells, J.M.; Rossi, O.; Meijerink, M.; van Baarlen, P. Epithelial crosstalk at the microbiota-mucosal interface. Proc. Natl. Acad. Sci. USA 2011, 108 (Suppl. 1), 4607-4614. [CrossRef] [PubMed]
26. Tremaroli, V.; Backhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489, 242-249. [CrossRef] [PubMed]
27. Fraher, M.H.; O’Toole, P.W.; Quigley, E.M. Techniques used to characterize the gut microbiota: A guide for the clinician. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 312-322. [CrossRef] [PubMed]
28. Panwar, H.; Rashmi, H.M.; Batish, V.K.; Grover, S. Probiotics as potential biotherapeutics in the management of type 2 diabetes—Prospects and perspectives. Diabetes/Metab. Res. Rev. 2013, 29, 103-112. [CrossRef] [PubMed]
29. Turnbaugh, P.J.; Ley, R.E.; Mahowald, M.A.; Magrini, V.; Mardis, E.R.; Gordon, J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027-1031. [CrossRef] [PubMed]
30. Ley, R.E.; Backhed, F.; Turnbaugh, P.; Lozupone, C.A.; Knight, R.D.; Gordon, J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA 2005, 102, 11070-11075. [CrossRef] [PubMed]
31. Backhed, F.; Manchester, J.K.; Semenkovich, C.F.; Gordon, J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. USA 2007, 104, 979-984. [CrossRef] [PubMed]
32. Larsen, N.; Vogensen, F.K.; van den Berg, F.W.; Nielsen, D.S.; Andreasen, A.S.; Pedersen, B.K.; Al-Soud, W.A.; Sorensen, S.J.; Hansen, L.H.; Jakobsen, M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 2010, 5, e9085. [CrossRef] [PubMed]
33. Cani, P.D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A.M.; Delzenne, N.M.; Burcelin, R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57, 1470-1481. [CrossRef] [PubMed]
34. Brown, J.M.; Hazen, S.L. The gut microbial endocrine organ: Bacterially derived signals driving cardiometabolic diseases. Ann. Rev. Med. 2015, 66, 343-359. [CrossRef] [PubMed]
35. Cashman, J.R.; Camp, K.; Fakharzadeh, S.S.; Fennessey, P.V.; Hines, R.N.; Mamer, O.A.; Mitchell, S.C.; Nguyen, G.P.; Schlenk, D.; Smith, R.L.; et al. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (fmo3) related to trimethylaminuria. Curr. Drug Metab. 2003, 4, 151-170. [CrossRef] [PubMed]
36. Tang, W.H.; Wang, Z.; Levison, B.S.; Koeth, R.A.; Britt, E.B.; Fu, X.; Wu, Y.; Hazen, S.L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013, 368, 1575-1584. [CrossRef] [PubMed]
37. Gao, X.; Liu, X.; Xu, J.; Xue, C.; Xue, Y.; Wang, Y. Dietary trimethylamine n-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J. Biosci. Bioeng. 2014, 118, 476-481. [CrossRef] [PubMed]
38. Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.M.; et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57-63. [CrossRef] [PubMed]
39. Koeth, R.A.; Wang, Z.; Levison, B.S.; Buffa, J.A.; Org, E.; Sheehy, B.T.; Britt, E.B.; Fu, X.; Wu, Y.; Li, L.; et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19, 576-585. [CrossRef] [PubMed]
40. Sanders, M.E. Probiotics: Definition, sources, selection, and uses. Clin. Infect. Dis. 2008, 46 (Suppl. 2), S58-S61. [CrossRef] [PubMed]
41. Sharp, M.D.; McMahon, D.J.; Broadbent, J.R. Comparative evaluation of yogurt and low-fat cheddar cheese as delivery media for probiotic lactobacillus casei. J. Food Sci. 2008, 73, M375-M377. [CrossRef] [PubMed]
42. Mann, G.V. A factor in yogurt which lowers cholesteremia in man. Atherosclerosis 1977, 26, 335-340. [CrossRef]
43. Nagpal, R.; Kumar, A.; Kumar, M.; Behare, P.V.; Jain, S.; Yadav, H. Probiotics, their health benefits and applicatio ns for developing healthier foods: A review. FEMS Microbiol. Lett. 2012, 334, 1-15. [CrossRef][PubMed]
44. Roberfroid, M.; Gibson, G.R.; Hoyles, L.; McCartney, A.L.; Rastall, R.; Rowland, I.; Wolvers, D.; Watzl, B.; Szajewska, H.; Stahl, B.; et al. Prebiotic effects: Metabolic and health benefits. Br. J. Nutr. 2010, 104 (Suppl. 2), S1-S63. [CrossRef] [PubMed]
45. Herich, R.; Levkut, M. Lactic acid bacteria, probiotics and immune system. Vet Med-Czech 2002, 47, 169-180.
46. Gill, H.S.; Rutherfurd, K.J.; Prasad, J.; Gopal, P.K. Enhancement of natural and acquired immunity by lactobacillus rhamnosus (HN001), lactobacillus acidophilus (HN017) and bifidobacterium lactis (HN019). Br. J. Nutr. 2000, 83, 167-176. [CrossRef] [PubMed]
47. Wu, X.; Ma, C.; Han, L.; Nawaz, M.; Gao, F.; Zhang, X.; Yu, P.; Zhao, C.; Li, L.; Zhou, A.; et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr. Microbiol. 2010, 61, 69-78. [CrossRef] [PubMed]
48. Amar, J.; Chabo, C.; Waget, A.; Klopp, P.; Vachoux, C.; Bermudez-Humaran, L.G.; Smirnova, N.; Berge, M.; Sulpice, T.; Lahtinen, S.; et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: Molecular mechanisms and probiotic treatment. EMBO Mol. Med. 2011, 3, 559-572. [CrossRef] [PubMed]
49. Naruszewicz, M.; Johansson, M.L.; Zapolska-Downar, D.; Bukowska, H. Effect of lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am. J. Clin. Nutr. 2002, 76, 1249-1255. [PubMed]
50. Jones, M.L.; Martoni, C.J.; Di Pietro, E.; Simon, R.R.; Prakash, S. Evaluation of clinical safety and tolerance of a lactobacillus reuteri ncimb 30242 supplement capsule: A randomized control trial. Regul. Toxicol. Pharmacol. RTP 2012, 63, 313-320. [CrossRef] [PubMed]
51. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergstrom, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Backhed, F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99-103. [CrossRef] [PubMed]
52. Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D.; et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490, 55-60. [CrossRef] [PubMed]
53. Ryan, P.M.; Ross, R.P.; Fitzgerald, G.F.; Caplice, N.M.; Stanton, C. Functional food addressing heart health: Do we have to target the gut microbiota? Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 566-571. [CrossRef] [PubMed]
54. Roberfroid, M. Prebiotics: The concept revisited. Am. Soc. Nutr. 2007, 137, 830S-837S.
55. Gibson, G.R.; Probert, H.M.; Loo, J.V.; Rastall, R.A.; Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutr. Res. Rev. 2004, 17, 259-275. [CrossRef] [PubMed]
56. Niness, K.R. Inulin and oligofructose: What are they? Am. Soc. Nutr. Sci. 1999, 129, 1402S-1406S.
57. Przemyslaw, J.; Tomasik, P.T. Probiotics and prebiotics. Cereal Chem. 2003, 80, 113-117.
58. Pourghassem Gargari, B.; Dehghan, P.; Aliasgharzadeh, A.; Asghari Jafar-abadi, M. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab. J. 2013, 37, 140-148. [CrossRef] [PubMed]
59. Fooks, L.J.; Gibson, G.R. In vitro investigations of the effect of probiotics and prebiotics on selected human intestinal pathogens. FEMS Microbiol. Ecol. 2002, 39, 67-75. [CrossRef] [PubMed]
60. Slavin, J. Fiber and prebiotics: Mechanisms and health benefits. Nutrients 2013, 5, 1417-1435. [CrossRef] [PubMed]
61. Parnell, J.A.; Reimer, R.A. Prebiotic fibres dose-dependently increase satiety hormones and alter bacteroidetes and firmicutes in lean and obese JCR:LA-cp rats. Br. J. Nutr. 2012, 107, 601-613. [CrossRef] [PubMed]
62. Everard, A.; Lazarevic, V.; Derrien, M.; Girard, M.; Muccioli, G.G.; Neyrinck, A.M.; Possemiers, S.; van Holle, A.; Francois, P.; Vos, W.M.; et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011, 60, 2775-2786. [CrossRef] [PubMed]
63. De Luca, C.; Olefsky, J.M. Inflammation and insulin resistance. FEBS Lett. 2008, 582, 97-105. [CrossRef] [PubMed]
64. Wang, J.; Tang, H.; Zhang, C.; Zhao, Y.; Derrien, M.; Rocher, E.; van-Hylckama Vlieg, J.E.; Strissel, K.; Zhao, L.; Obin, M.; Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2015, 9, 1-15. [CrossRef] [PubMed]
65. Wellen, K.E.; Hotamisligil, G.S. Inflammation, stress, and diabetes. J. Clin. Investig. 2005, 115, 1111-1119. [CrossRef] [PubMed]
66. Ahren, B.; Schmitz, O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res. 2004, 36, 867-876. [CrossRef] [PubMed]
67. Asemi, Z.; Zare, Z.; Shakeri, H.; Sabihi, S.S.; Esmaillzadeh, A. Effect of multispecies probiotic supplements on metabolic profiles, HS-CRP, and oxidative stress in patients with type 2 diabetes. Ann. Nutr. Metab. 2013, 63, 1-9. [CrossRef] [PubMed]
68. Ejtahed, H.S.; Mohtadi-Nia, J.; Homayouni-Rad, A.; Niafar, M.; Asghari-Jafarabadi, M.; Mofid, V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012, 28, 539-543. [CrossRef] [PubMed]
69. Yadav, H.; Jain, S.; Sinha, P.R. Oral administration of dahi containing probiotic lactobacillus acidophilus and lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J. Dairy Res. 2008, 75, 189-195. [CrossRef] [PubMed]
70. Yadav, H.; Jain, S.; Sinha, P.R. Antidiabetic effect of probiotic dahi containing lactobacillus acidophilus and lactobacillus casei in high fructose fed rats. Nutrition 2007, 23, 62-68. [CrossRef] [PubMed]
71. Mahboobi, S.; Iraj, B.; Maghsoudi, Z.; Feizi, A.; Ghiasvand, R.; Askari, G.; Maayeshi, N. The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: A randomized clinical trial. Int. J. Prev. Med. 2014, 5, 1239-1246. [PubMed]
72. Andreasen, A.S.; Larsen, N.; Pedersen-Skovsgaard, T.; Berg, R.M.; Moller, K.; Svendsen, K.D.; Jakobsen, M.; Pedersen, B.K. Effects of lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br. J. Nutr. 2010, 104, 1831-1838. [CrossRef] [PubMed]
73. Lewis, S.J.; Burmeister, S. A double-blind placebo-controlled study of the effects of lactobacillus acidophilus on plasma lipids. Eur. J. Clin. Nutr. 2005, 59, 776-780. [CrossRef] [PubMed]
74. Fukushima, M.; Yamada, A.; Endo, T.; Nakano, M. Effects of a mixture of organisms, lactobacillus acidophilus or streptococcus faecalis on delta 6-desaturase activity in the livers of rats fed a fat- and cholesterol-enriched diet. Nutrition 1999, 15, 373-378. [CrossRef]
75. Abd El-Gawad, I.A.; El-Sayed, E.M.; Hafez, S.A.; El-Zeini, H.M.; Saleh, F.A. The hypocholesterolaemic effect of milk yoghurt and soy-yoghurt containing bifidobacteria in rats fed on a cholesterol-enriched diet. Int. Dairy J. 2005, 15, 37-44. [CrossRef]
76. Nguyen, T.D.; Kang, J.H.; Lee, M.S. Characterization of lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol-lowering effects. Int. J. Food Microbiol. 2007, 113, 358-361. [CrossRef] [PubMed]
77. Kim, M.; Shin, H.K. The water-soluble extract of chicory influences serum and liver lipid concentrations, cecal short-chain fatty acid concentrations and fecal lipid excretion in rats. J. Nutr. 1998, 128, 1731-1736. [PubMed]
78. Anderson, J.W.; Gilliland, S.E. Effect of fermented milk (yogurt) containing lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J. Am. Coll Nutr. 1999, 18, 43-50. [CrossRef] [PubMed]
79. Xiao, J.Z.; Kondo, S.; Takahashi, N.; Miyaji, K.; Oshida, K.; Hiramatsu, A.; Iwatsuki, K.; Kokubo, S.; Hosono, A. Effects of milk products fermented by bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J. Dairy Sci. 2003, 86, 2452-2461. [CrossRef]
80. Simons, L.A.; Amansec, S.G.; Conway, P. Effect of lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr. Metab. Cardiovas 2006, 16, 531-535. [CrossRef] [PubMed]
81. Fabian, E.; Elmadfa, I. Influence of daily consumption of probiotic and conventional yoghurt on the plasma lipid profile in young healthy women. Ann. Nutr. Metab. 2006, 50, 387-393. [CrossRef] [PubMed]
82. Hatakka, K.; Mutanen, M.; Holma, R.; Saxelin, M.; Korpela, R. Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids. J. Am. Coll Nutr. 2008, 27, 441-447. [CrossRef] [PubMed]
83. Brighenti, F.; Casiraghi, M.C.; Canzi, E.; Ferrari, A. Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. Eur. J. Clin. Nutr. 1999, 53, 726-733. [CrossRef] [PubMed]
84. Causey, J.L.; Feirtag, J.M.; Gallaher, D.D.; Tungland, B.C.; Slavin, J.L. Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal, environment in hypercholesterolemic men. Nutr. Res. 2000, 20, 191-201. [CrossRef]
85. Dikeman, C.L.; Murphy, M.R.; Fahey, G.C., Jr. Dietary fibers affect viscosity of solutions and simulated human gastric and small intestinal digesta. J. Nutr. 2006, 136, 913-919. [PubMed]
86. Shen, J.; Obin, M.S.; Zhao, L.P. The gut microbiota, obesity and insulin resistance. Mol. Aspects. Med. 2013, 34, 39-58. [CrossRef] [PubMed]
87. Delzenne, N.M.; Neyrinck, A.M.; Backhed, F.; Cani, P.D. Targeting gut microbiota in obesity: Effects of prebiotics and probiotics. Nat. Rev. Endocrinol. 2011, 7, 639-646. [CrossRef] [PubMed]
88. Everard, A.; Cani, P.D. Diabetes, obesity and gut microbiota. Best Pract. Res. Cl Ga 2013, 27, 73-83. [CrossRef] [PubMed]
89. Cani, P.D.; Osto, M.; Geurts, L.; Everard, A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012, 3, 279-288. [CrossRef] [PubMed]
90. Musso, G.; Gambino, R.; Cassader, M. Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded? Diabetes Care 2010, 33, 2277-2284. [CrossRef] [PubMed]
91. Furet, J.P.; Kong, L.C.; Tap, J.; Poitou, C.; Basdevant, A.; Bouillot, J.L.; Mariat, D.; Corthier, G.; Dore, J.; Henegar, C. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: Links with metabolic and low-grade inflammation markers. Diabetes 2010, 59, 3049-3057. [CrossRef] [PubMed]
92. Cani, P.D. Gut microbiota and obesity: Lessons from the microbiome. Brief. Funct. Genom. 2013, 12, 381-387. [CrossRef] [PubMed]
93. Bindels, L.B.; Dewulf, E.M.; Delzenne, N.M. GPR43/FFA2: Physiopathological relevance and therapeutic prospects. Trends Pharmacol. Sci. 2013, 34, 226-232. [CrossRef] [PubMed]
94. Delzenne, N.M.; Cani, P.D.; Daubioul, C.; Neyrinck, A.M. Impact of inulin and oligofructose on gastrointestinal peptides. Br. J. Nutr. 2005, 93 (Suppl. 1), S157-S161. [CrossRef] [PubMed]
95. Delzenne, N.M.; Cani, P.D.; Neyrinck, A.M. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: Experimental data. J. Nutr. 2007, 137, 2547S-2551S. [PubMed]
96. Cani, P.D.; Dewever, C.; Delzenne, N.M. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br. J. Nutr. 2004, 92, 521-526. [CrossRef] [PubMed]
97. Yin, Y.N.; Yu, Q.F.; Fu, N.; Liu, X.W.; Lu, F.G. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J. Gastroenterol. 2010, 16, 3394-3401. [CrossRef] [PubMed]
98. Delzenne, N.M.; Kok, N. Effects of fructans-type prebiotics on lipid metabolism. Am. J. Clin. Nutr. 2001, 73, 456s-458s. [PubMed]
99. Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; Tcheang, L.; Daniels, D.; Muir, A.I.; Wigglesworth, M.J.; Kinghorn, I.; Fraser, N.J. The orphan g protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278, 11312-11319. [CrossRef] [PubMed]
100. Holst, J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87, 1409-1439. [CrossRef] [PubMed]
101. Madsbad, S. Exenatide and liraglutide: Different approaches to develop GLP-1 receptor agonists (incretin mimetics)—Preclinical and clinical results. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23, 463-477. [CrossRef] [PubMed]
102. Tolhurst, G.; Heffron, H.; Lam, Y.S.; Parker, H.E.; Habib, A.M.; Diakogiannaki, E.; Cameron, J.; Grosse, J.; Reimann, F.; Gribble, F.M. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012, 61, 364-371. [CrossRef] [PubMed]
103. Ge, H.; Li, X.; Weiszmann, J.; Wang, P.; Baribault, H.; Chen, J.L.; Tian, H.; Li, Y. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008, 149, 4519-4526. [CrossRef] [PubMed]
104. Kimura, I.; Ozawa, K.; Inoue, D.; Imamura, T.; Kimura, K.; Maeda, T.; Terasawa, K.; Kashihara, D.; Hirano, K.; Tani, T. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 2013, 4, 1829. [CrossRef] [PubMed]
105. Hong, Y.H.; Nishimura, Y.; Hishikawa, D.; Tsuzuki, H.; Miyahara, H.; Gotoh, C.; Choi, K.C.; Feng, D.D.; Chen, C.; Lee, H.G.; et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005, 146, 5092-5099. [CrossRef] [PubMed]
106. Samuel, B.S.; Shaito, A.; Motoike, T.; Rey, F.E.; Backhed, F.; Manchester, J.K.; Hammer, R.E.; Williams, S.C.; Crowley, J.; Yanagisawa, M. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, GPR41. Proc. Natl. Acad. Sci. USA 2008, 105, 16767-16772. [CrossRef] [PubMed]
107. Holman, J. Methods of salt iodization. Boletin de la Oficina Sanitaria Panamericana. Pan Am. Sanit. Bur. 1966, 60, 139-143.
108. Kimura, I.; Inoue, D.; Maeda, T.; Hara, T.; Ichimura, A.; Miyauchi, S.; Kobayashi, M.; Hirasawa, A.; Tsujimoto, G. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc. Natl. Acad. Sci. USA 2011, 108, 8030-8035. [CrossRef] [PubMed]
109. Inoue, D.; Kimura, I.; Wakabayashi, M.; Tsumoto, H.; Ozawa, K.; Hara, T.; Takei, Y.; Hirasawa, A.; Ishihama, Y.; Tsujimoto, G. Short-chain fatty acid receptor gpr41-mediated activation of sympathetic neurons involves synapsin 2B phosphorylation. FEBS Lett. 2012, 586, 1547-1554. [CrossRef] [PubMed]
110. Demigne, C.; Morand, C.; Levrat, M.A.; Besson, C.; Moundras, C.; Remesy, C. Effect of propionate on fatty-acid and cholesterol-synthesis and on acetate metabolism in isolated rat hepatocytes. Br. J. Nutr. 1995, 74, 209-219. [CrossRef] [PubMed]
111. Trautwein, E.A.; Rieckhoff, D.; Erbersdobler, H.F. Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamster. J. Nutr. 1998, 128, 1937-1943. [PubMed]
112. Gabel, G.; Aschenbach, J.R.; Muller, F. Transfer of energy substrates across the rumin al epithelium: Implications and limitations. Anim. Health Res. Rev. 2002, 3, 15-30. [CrossRef] [PubMed]
113. Sukonina, V.; Lookene, A.; Olivecrona, T.; Olivecrona, G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA 2006, 103, 17450-17455. [CrossRef] [PubMed]
114. Yoshida, K.; Shimizugawa, T.; Ono, M.; Furukawa, H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 2002, 43, 1770-1772. [CrossRef] [PubMed]
115. Kersten, S.; Mandard, S.; Tan, N.S.; Escher, P.; Metzger, D.; Chambon, P.; Gonzalez, F.J.; Desvergne, B.; Wahli, W. Characterization of the fasting-induced adipose factor fiaf, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 2000, 275, 28488-28493. [CrossRef] [PubMed]
116. Ferré, P. The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 2005, 53, S43-S50. [CrossRef]
117. Mandard, S.; Zandbergen, F.; Tan, N.S.; Escher, P.; Patsouris, D.; Koenig, W.; Kleemann, R.; Bakker, A.; Veenman, F.; Wahli, W.; et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J. Biol. Chem. 2004, 279, 34411-34420. [CrossRef] [PubMed]
118. Koster, A.; Chao, Y.B.; Mosior, M.; Ford, A.; Gonzalez-DeWhitt, P.A.; Hale, J.E.; Li, D.; Qiu, Y.; Fraser, C.C.; Yang, D.D. Transgenic angiopoietin-like (ANGPTL)4 overexpression and targeted disruption of ANGPTL4 and ANGPTL3: Regulation of triglyceride metabolism. Endocrinology 2005, 146, 4943-4950. [CrossRef] [PubMed]
119. Backhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenkovich, C.F.; Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 2004, 101, 15718-15723. [CrossRef] [PubMed]
120. Mattijssen, F.; Alex, S.; Swarts, H.J.; Groen, A.K.; van Schothorst, E.M.; Kersten, S. ANGPTL4 serves as an endogenous inhibitor of intestinal lipid digestion. Mol. Metab. 2014, 3, 135-144. [CrossRef] [PubMed]
121. Jones, M.L.; Chen, H.; Ouyang, W.; Metz, T.; Prakash, S. Microencapsulated genetically engineered lactobacillus plantarum 80 (PCBH1) for bile acid deconjugation and its implication in lowering cholesterol. J. Biomed. Biotechnol. 2004, 2004, 61-69. [CrossRef] [PubMed]
122. Ooi, L.G.; Liong, M.T. Cholesterol-lowering effects of probiotics and prebiotics: A review of in vivo and in vitro findings. Int. J. Mol. Sci. 2010, 11, 2499-2522. [CrossRef] [PubMed]
123. Begley, M.; Hill, C.; Gahan, C.G. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 2006, 72, 1729-1738. [CrossRef] [PubMed]
124. Williams, C.M. Effects of inulin on lipid parameters in humans. J. Nutr. 1999, 129, 1471S-1473S. [PubMed]
125. Tan, K.P.; Yang, M.; Ito, S. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol. Pharmacol. 2007, 72, 1380-1390. [CrossRef] [PubMed]
126. Trauner, M.; Meier, P.J.; Boyer, J.L. Molecular pathogenesis of cholestasis. N. Engl. J. Med. 1998, 339, 1217-1227. [PubMed]
127. Beilke, L.D.; Besselsen, D.G.; Cheng, Q.; Kulkarni, S.; Slitt, A.L.; Cherrington, N.J. Minimal role of hepatic transporters in the hepatoprotection against lca-induced intrahepatic cholestasis. Toxicol. Sci. 2008, 102, 196-204. [CrossRef] [PubMed]
128. Deichelbohrer, I.; Alonso, J.C.; Luder, G.; Trautner, T.A. Plasmid transduction by Bacillus subtilis bacteriophage SPP1: Effects of DNA homology between plasmid and bacteriophage. J. Bacteriol. 1985, 162, 1238-1243. [PubMed]
129. Merryweather, A.; Barth, P.T.; Wilkins, B.M. Role and spec ificity of plasmid RP4-encoded DNA primase inbacterial conjugation. J. Bacteriol. 1986, 167, 12-17. [PubMed]
130. Mathur, S.; Singh, R. Antibiotic resistance in food lactic acid bacteria—A review. Int. J. Food Microbiol. 2005, 105, 281-295. [CrossRef] [PubMed]
131. Zvenigorodskii, V.I.; Pozdniakov, V.N.; Bugaichuk, IuD.; Zhdanov, V.G. Transformation of Bacillus licheniformis by plasmid DNA. Genetika 1983, 19, 1036-1038. [PubMed]